WWWendy I. White

Wendy I. White

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wendy I. White has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab

    by Weifeng Tang, Raj Tummala, Joachim Almquist, Michael Hwang, Wendy I. White, David W. Boulton, Alexander MacDonald

    The type I interferon (IFN) signaling pathway is implicated in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab is a monoclonal antibody that targets the type I IFN receptor subunit 1. Anifrolumab is approved in several countries for patients with moderate to severe SLE receiving standard therapy. The approved dosing regimen of anifrolumab is a 300-mg dose administered intravenously every 4 weeks; this was initially based on the results of the Phase 2b MUSE and further confirmed in the Phase 3 TULIP-1 and TULIP-2 trials, in which anifrolumab 300-mg treatment was associated with clinically meaningful improvements in disease activity with an acceptable safety profile. There have been several published analyses of the pharmacokinetic and pharmacodynamic profile of anifrolumab, including a population–pharmacokinetic analysis of 5 clinical studies of healthy volunteers and patients with SLE, in which body weight and type I IFN gene expression were significant covariates identified for anifrolumab exposure and clearance. Additionally, the pooled Phase 3 SLE population has been used to evaluate how serum exposure may be related to clinical responses, safety risks, and pharmacodynamic effects of the 21-gene type I IFN gene signature (21-IFNGS). The relevance of 21-IFNGS with regard to clinical efficacy outcomes has also been analyzed. Herein, the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of anifrolumab as well as results of population–pharmacokinetics and exposure–response analyses are reviewed.


  • Open Access

    FRI0256 Effects of anifrolumab on oxidative stress and macrophage activation: novel biomarkers and impact of type i interferon blockade in systemic lupus erythematosus

    by X. Guo, S. Wang, L. Wang, L.K. Roskos, W.I. White

    Background Type I interferons (IFNs) drive several aspects of systemic lupus erythematosus (SLE) etiology and pathophysiology. Anifrolumab, a fully human anti-IFN-α receptor monoclonal antibody, substantially reduced disease activity compared with placebo in a Phase IIb study of SLE patients.1 Previous results indicated beneficial effects of anifrolumab on dysregulated lymphocyte, neutrophil, and complement systems in SLE.2 However, the impact of type I IFN blockade remains to be fully elucidated. Objectives We characterised biomarkers for oxidative stress and macrophage activation in SLE and assessed downstream effects of anifrolumab on those two key disease pathways. Methods In the MUSE study,1 305 patients with moderate to severe SLE were randomised in a 1:1:1 ratio to receive placebo or anifrolumab (300 or 1,000 mg) every 4 weeks for 48 weeks. A four-gene expression assay was used to define type I IFN gene signature (IFNGS) test status. In our study, four protein biomarkers were measured in sera of healthy controls (HCs) and SLE patients with samples available at baseline, and 85, 169, and 365 days after administration, using a multiplex luminex immunoassay. Wilcoxon rank-sum test was used to evaluate baseline protein concentrations and posttreatment changes between different groups. Results Two oxidative stress biomarkers, peroxiredoxin 4 (PRDX4) and aldose reductase (AKR1B1), were found in greater serum concentrations in 195 SLE patients than in 20 HCs (pConclusions Our results identified PRDX4 as an oxidative stress marker and FOLR3 as a macrophage activation marker associated with disease activities and type I IFNGS test status in SLE. Anifrolumab administration elicits reduced oxidative stress and decreased monocyte/macrophage activation, which may contribute to the clinical efficacy of anifrolumab in SLE patients. References [1] Furie R, et al. Arthritis Rheumatol. 2017;69:376–86. [2] Guo X, et al. Ann. Rheum. Dis. 2016;75:118. Disclosure of Interest X. Guo Shareholder of: AstraZeneca, Employee of: MedImmune, S. Wang Shareholder of: AstraZeneca, Employee of: MedImmune, L. Wang Shareholder of: AstraZeneca, Employee of: AstraZeneca, L. Roskos Shareholder of: AstraZeneca, Employee of: AstraZeneca, W. White Shareholder of: AstraZeneca, Employee of: MedImmune